COAG (COAG)
44.41
+0.04 (0.09%)
Upcoming Events
Latest Headlines
/C O R R E C T I O N -- The Galien Foundation/
August 17, 2026 4:14 AM - PR NewsWire
Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Novo Holdings A/S
August 14, 2026 5:07 PM - SEC Filing
Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Avoro Capital Advisors LLC
August 14, 2026 9:02 AM - SEC Filing
The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and &q
August 13, 2026 9:00 AM - PR NewsWire
Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Capital International Investors
August 12, 2026 10:28 AM - SEC Filing
Hemab Therapeutics Holdings (COAG) PT Raised to $60 at H.C. Wainwright
August 12, 2026 7:21 AM - StreetInsider
Form 10-Q Hemab Therapeutics Holdi For: Jun 30
August 11, 2026 4:01 PM - SEC Filing
Hemab Therapeutics Holdings (COAG) PT Raised to $58 at Jefferies
August 11, 2026 3:30 PM - StreetInsider
Form 8-K Hemab Therapeutics Holdi For: Aug 11
August 11, 2026 7:11 AM - SEC Filing
Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026 7:00 AM - StreetInsider
Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Invus Global Management, LLC
August 7, 2026 9:32 AM - SEC Filing
Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: FMR LLC
August 6, 2026 10:28 AM - SEC Filing
Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Sofinnova Crossover II S.L.P.
August 5, 2026 10:38 AM - SEC Filing
Hemab shares sutacimig Phase 2 data at ISTH 2026 congress
July 14, 2026 7:45 AM - StreetInsider
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
July 14, 2026 7:45 AM - StreetInsider
Hemab Therapeutics Holdings (COAG) PT Raised to $47 at Jefferies
July 13, 2026 8:51 AM - StreetInsider
Hemab Therapeutics Holdings (COAG) PT Raised to $52 at H.C. Wainwright
July 13, 2026 6:38 AM - StreetInsider
Hemab shares clinical data on HMB-002, unveils HMB-003 program
July 13, 2026 5:44 AM - StreetInsider
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
July 12, 2026 6:28 AM - Globe NewsWire
Hemab Therapeutics to present pipeline data at ISTH 2026
June 26, 2026 9:00 AM - StreetInsider
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
June 26, 2026 9:00 AM - StreetInsider
Form 4 Hemab Therapeutics Holdi For: Jun 15 Filed by: Kolchinsky Peter
June 17, 2026 6:24 PM - SEC Filing
H.C. Wainwright Starts Hemab Therapeutics Holdings (COAG) at Buy
June 17, 2026 5:59 AM - StreetInsider
Full Article List